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Objective Haemophilus influenzae type b (Hib) vaccine was introduced into routine immunization services in Kenya in 2001. We 
aimed to estimate the cost-effectiveness of Hib vaccine delivery.
Methods A model was developed to follow the Kenyan 2004 birth cohort until death, with and without Hib vaccine. Incidence of 
invasive Hib disease was estimated at Kilifi District Hospital and in the surrounding demographic surveillance system in coastal Kenya. 
National Hib disease incidence was estimated by adjusting incidence observed by passive hospital surveillance using assumptions 
about access to care. Case fatality rates were also assumed dependent on access to care. A price of US$ 3.65 per dose of pentavalent 
diphtheria-tetanus-pertussis-hep B-Hib vaccine was used. Multivariate Monte Carlo simulations were performed in order to assess 
the impact on the cost-effectiveness ratios of uncertainty in parameter values.
Findings The introduction of Hib vaccine reduced the estimated incidence of Hib meningitis per 100 000 children aged < 5 years 
from 71 to 8; of Hib non-meningitic invasive disease from 61 to 7; and of non-bacteraemic Hib pneumonia from 296 to 34. The 
costs per discounted disability adjusted life year (DALY) and per discounted death averted were US$ 38 (95% confidence interval, 
CI: 26–63) and US$ 1197 (95% CI: 814–2021) respectively. Most of the uncertainty in the results was due to uncertain access to 
care parameters. The break-even pentavalent vaccine price – where incremental Hib vaccination costs equal treatment costs averted 
from Hib disease – was US$ 1.82 per dose.
Conclusion Hib vaccine is a highly cost-effective intervention in Kenya. It would be cost-saving if the vaccine price was below half 
of its present level.
Bulletin of the World Health Organization 2007;85:511–518.
Une traduction en français de ce résumé figure à la fin de l’article. Al final del artículo se facilita una traducción al español.
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Introduction
Haemophilus influenzae type b (Hib) vac-
cine has been licensed for use in infants 
since 1991. Most industrialized countries 
introduced the vaccine quickly into rou-
tine infant immunization services. This 
was justified by observed annual inci-
dence rates of Hib meningitis between 
20 and 69 cases per 100 000 children 
under five years old.1 Middle-income 
and developing countries have been 
hesitant to introduce the vaccine be-
cause of its relatively high price and the 
problem of establishing the Hib disease 
burden in areas with very little surveil-
lance. However, since 2001 the GAVI 
Alliance (previously the Global Alliance 
for Vaccines and Immunization) has 
provided financial support for new and 
underused vaccines in 72 low-income 
countries.2  By July 2005, GAVI sup-
ported the introduction of Hib vaccine 
in 17 of these countries, usually delivered 
in combination with diphtheria-tetanus-
pertussis (DTP) and hepatitis B vaccines 
as a pentavalent vaccine.2
Kenya was among the first nine 
countries to receive financial support 
from GAVI, and pentavalent vaccine 
was introduced nationwide in No-
vember 2001. GAVI’s financial com-
mitment for new vaccines in Kenya 
was US$ 67.4 million over a five-year 
period,2 after which it was anticipated 
that the vaccine price would decrease 
substantially – an expectation yet to be 
realized. Support was planned to end 
in 2006, but recently GAVI offered to 
extend assistance through 2006–2015 
with country co-financing. GAVI’s 
phase II strategy is that recipient coun-
tries make progressive increases to their 
contributions to vaccine costs so that 
they reach market prices by 2016.3 In 
2007 the Kenyan Government agreed 
to co-finance the pentavalent vaccine 
with US$ 0.38 per dose for the period 
2006-2011 (letter from Minister of 
Health to GAVI, 18 April 2007). Hib 
vaccination is a new cost item in the 
Kenyan Government’s health budget; 
therefore cost-effectiveness evidence is 
likely to be crucial when deciding on 
future financial support. The objective 
of this study was to estimate the incre-
mental costs per case, death and DALY, 
averted by delivering Hib vaccine in 
routine infant immunization services in 
Kenya.
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Methods
A model was developed to follow the 
2004 birth cohort until death. Two sce-
narios were constructed: one with Hib 
vaccine in routine immunization ser-
vices and one without. Only immediate 
costs of care were estimated, excluding 
the costs of providing long-term care for 
patients with severe sequelae. The analy-
sis was carried out from a public health 
provider perspective; costs incurred by 
households were not included. The 2004 
average exchange rate of 79.49 Kenyan 
shillings to US$ 1 was used in all calcu-
lations. All future costs and outcomes 
were discounted at 3% per year.
Hib disease incidence
Pneumonia is the most common mani-
festation of Hib disease in developing 
countries.4 Findings from Hib vaccine 
trials in the Gambia and Chile illus-
trate that reductions in radiologically 
proven pneumonia cases were approxi-
mately five times those in Hib meningitis 
cases.5–7 However, difficulties in estab-
lishing a definitive diagnosis of Hib dis-
ease in most parts of the world mean that 
the true disease burden remains largely 
unknown.4,8 Hib disease is divided into 
three categories in this study: (a) Hib 
meningitis, (b) non-meningitic invasive 
Hib disease (mainly bacteraemic Hib 
pneumonia, but also severe sepsis with 
an unknown focus of infection), and (c) 
non-bacteraemic Hib pneumonia.
Age-specific incidences of category 
(a) and (b) before and after the intro-
duction of Hib vaccine were estimated 
from hospital admission records at Kilifi 
District Hospital (KDH) between 2000 
and 2005. KDH is a rural government-
funded hospital with 42 paediatric beds 
and approximately 5000 paediatric 
admissions per year. A Kenya Medical 
Research Institute (KEMRI) centre at 
the hospital has been conducting re-
search on common childhood illnesses 
since 1989. Data on paediatric invasive 
bacterial infections, including routine 
blood cultures on all children admitted 
to hospital, have been collected since 
1998.9 Cases of Hib invasive disease 
were categorized as meningitis if a 
cerebrospinal fluid (CSF) specimen 
yielded a positive Hib culture, a posi-
tive Hib antigen test, or had an elevated 
CSF white cell count in the presence 
of a blood culture positive for Hib. If 
a positive blood culture was the only 
evidence of Hib disease, the case was 
classified as non-meningitic invasive Hib 
disease.10 Detailed criteria for detecting 
meningitis cases, collecting specimens 
and laboratory processing at KDH have 
been published elsewhere.9,11
Since 2000, KEMRI has conducted 
a demographic surveillance study (DSS) 
in an 891 km² area around the hospital: 
25 000 households are visited and re-
enumerated every six months. Hib cases 
admitted to KDH from within the DSS 
area were linked to age-specific popula-
tion denominators to estimate annual 
incidence rates of invasive Hib disease 
detected by passive hospital surveil-
lance.11 The hospital incidence of Hib 
invasive disease per 100 000 children 
aged < 5 years was 66 (95% confidence 
interval, CI: 49.6–81.6) before the in-
troduction of Hib vaccine (2000/2001) 
and 7.6 (95% CI: 1.6–22.3) three years 
after its introduction (2004/2005).11 
However, these estimates underestimate 
the true incidence, as a relatively large 
proportion of children in Kenya have 
limited access to health care and there-
fore would not be detected by hospital 
surveillance. Even within the Kilifi DSS, 
the area closest to the hospital, only 
one-third of childhood deaths occur in 
hospital, and one-third of children who 
die access only primary health-care fa-
Table 1. Parameters for estimating burden of Hib disease in Kenya before and after vaccine introduction
Parameter Base case 
value
Range used in 
uncertainty analysis
Ref.
2004 birth cohort 1 322 000 – 24
Pentavalent & DTP+hep B vaccine coverage of 3rd dose 73% 70–75% 24
Types of Hib disease:
Meningitis of total invasive Hib disease 54% 52–56% 11
Non-meningitic invasive disease of total invasive Hib disease 46% – 11
Hib pneumonia:Hib meningitis cases 5:1 SD 0.5 5–7
Hib invasive disease hospital incidence:
Before Hib vaccine introduction 66 49.6–81.6 11
After Hib vaccine introduction 7.60 1.6–22.3 11
Access to health care for children < 5 years with Hib disease:
Hospital care 50% 30–70% 12,13
Outpatient care 25% 15–35% 12,13
No access to formal care 25% 15–35% 12,13 
Case fatality rates for children < 5 years:
Hib meningitis + hospital treatment 17% 7–44% 16,25
Hib meningitis & non-meningitis invasive Hib disease + outpatient treatment 63% 40–90% 26
Hib meningitis & Hib non-meningitis invasive disease + no biomedical treatment 97% 80–100% Assumption
Non-meningitis invasive Hib disease + hospital treatment 26% 7–44% 9
Non-bacteraemic Hib pneumonia + hospital treatment 3.5% 2.5–4.5% Assumption
Non-bacteraemic Hib pneumonia + outpatient treatment only 7% 2.5–10% Assumption
Non-bacteraemic Hib pneumonia + no biomedical treatment 25% 15–35% 27
DTP, diphtheria-tetanus-pertussis; hep B, hepatitis B; Hib, Haemophilus influenzae type b; SD, standard deviation.
513Bulletin of the World Health Organization | July 2007, 85 (7)
Research
Economic evaluation of delivering H. influenzae vaccine in KenyaAngela Oloo Akumu et al.
cilities during their terminal illness.12,13 
These findings are consistent with data 
from rural communities elsewhere 
in Kenya.14 Based on these data, and 
adopting a conservative approach to 
take account of better access in urban 
communities, we estimated that 50% 
of Hib disease cases were detected by 
passive hospital-based surveillance. The 
true incidence of Hib invasive disease 
in children aged < 5 years was therefore 
calculated as twice that observed in the 
Kilifi study (Table 1).
Non-bacteraemic Hib pneumonia 
was not included in the surveillance 
at KDH as currently there is no diag-
nostic tool other than blood culture 
to determine accurately the etiology of 
pneumonia.8 The incidence of category 
(c) was therefore estimated from the 5:1 
ratio between Hib meningitis and pneu-
monia referred to above. The incidence 
of disease category (b) was subtracted to 
avoid double-counting of bacteraemic 
pneumonia. Case fatality rates were var-
ied according to the type of health care 
received, as summarized in Table 1.
Disability adjusted life years 
(DALYs) were estimated using the 
method recommended in the 1996 
global burden of disease study.15 Age 
weighting was included. The disability 
weight is 0.616 for the acute phase of 
bacterial meningitis and 0.28 for an 
episode of non-meningitic invasive Hib 
disease and non-bacteraemic pneumo-
nia.15 For survivors, we assumed that all 
episodes last one month. At KDH, 25% 
of Hib meningitis survivors suffer from 
clinically obvious significant neuro-
logical sequelae, predominantly motor 
deficits.16 Therefore, we applied the dis-
ability weight for motor deficits (0.334) 
to meningitis sequelae and assumed that 
the sequelae last throughout the pa-
tients’ lives. More minor sequelae (such 
as epilepsy) and even major non-motor 
sequelae (such as isolated sensorineural 
deafness) were not accounted for.
Vaccine delivery costs
The current costs of including pen-
tavalent vaccine in the routine im-
munization schedule were compared 
to a hypothetical scenario using the 
diphtheria-tetanus-pertussis-hepatitis B 
combination without Hib vaccine. As 
all vaccines and injection equipment are 
procured through the United Nations 
Children’s Fund (UNICEF), we used 
the 2004 vaccine and syringe prices of 
the UNICEF supply division.17 Other 
vaccine delivery costs, such as staff sala-
ries and transport, were not included. 
These would not be affected markedly 
as there is no difference in the number 
of health service contacts for the two 
different types of vaccines. Ministry of 
Health staff members were interviewed 
in order to assess other costs related to 
vaccine introduction, such as enhanced 
surveillance and training activities.
Hib disease treatment costs
Hospital treatment costs were divided 
into patient-specific costs and costs per 
patient bed-day. Patient-specific costs of 
Hib meningitis and non-meningitic in-
vasive Hib disease were estimated from 
patient records at KDH. We reviewed 
the hospital records of 31 children ad-
mitted in 2001 with proven invasive 
Hib disease (21 meningitis and 10 
non-meningitic invasive disease) and ex-
tracted information on diagnostic tests, 
drugs administered and the length of 
hospital stay. Data from the six children 
who died were included in the analysis. 
However, as KDH is a research setting, 
certain diagnostic tests and treatment 
procedures differ from standard Kenyan 
practices. To avoid inflating the national 
cost estimates we substituted KDH costs 
for third-generation cephalosporins, not 
currently recommended as first-line 
antibiotic therapy in Kenya, with costs 
for penicillin and chloramphenicol, and 
excluded blood culture costs. For non-
bacteraemic Hib pneumonia, patient-
specific data on resource usage were 
collected from a total of 76 pneumonia 
patient records at three district hospitals: 
Homa Bay, Kitui and Kerugoya.
Unit costs for drugs were collected 
largely from the Kenya Medical Supplies 
Agency (KEMSA). Costs per bed-day 
and per outpatient visit were taken from 
the WHO-CHOICE database.18 We 
used cost data for a secondary hospital, as 
we believe this provides the best average 
cost estimate for a national-level analysis. 
In 2004 values, the costs per bed-day 
and per outpatient visit were US$ 6.57 
and US$ 1.92 respectively. The assump-
tions on access to care summarized in 
Table 1 were used to calculate treatment 
costs for the country as a whole.
Uncertainty and sensitivity 
analysis
We undertook a probabilistic multi-
variate analysis to assess the impact 
of uncertainty in parameter values. 
Prediction intervals around the mean 
cost-effectiveness ratios were derived 
from 50 000 Monte Carlo simulations 
by Crystal Ball software (Decisioneering, 
USA). For the disease burden parameters 
we assumed either triangular or normal 
Table 2.  Model estimates of cases and deaths from Hib disease with and without Hib vaccine delivery in the 2004 Kenyan 
birth cohort
Hib cases and deaths without Hib vaccine Hib cases and deaths with Hib vaccine
Age in 
years
 Menin-
gitis 
cases
Non-
meningitic 
invasive 
cases
Non-
bacteraemic 
pneumonia 
cases
Total 
cases
Total 
deaths
 Menin-
gitis 
cases
Non-
meningitic 
invasive 
cases
Non-
bacteraemic 
pneumonia 
cases
Total 
cases
Total 
deaths
0 2921 2488 12117 7526 3917 336 287 1395 2018 451
1 889 757 3688 5334 1192 102 87 425 614 137
2 452 385 1873 2709 605 52 44 216 312 70
3 198 168 819 1185 265 23 19 94 136 31
4 99 84 410 593 132 11 10 47 68 15
Total 4558 3883 18 907 27 347  6112 525 447 2177 3149 704
Hib, Haemophilus influenzae type b.
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Table 3. Estimated annual cost (US$) of vaccines and injection equipment in Kenyan public health sector with and without the 
pentavalent vaccine (2004)
Antigen Dose
per  
vial
Wast-
age  
(%)
Costs 
per dose 
(including 
freight)
No. of 
children 
reached
Total 
vaccine 
costs
Injection 
supply 
costsa
Total % of 
total
Bacille Calmette–Guérin 20 70 0.10  1 150 140 372 645 86 133 458 778 3.2%
DTP+hep B+Hib (pentavalent) 2 15 3.70  965 060 12 618 727 305 519 12 924 246 89.6%
Measles 10 65 0.17 900 820 150 329 70 815 221 144 1.5%
Oral polio vaccine 20 10 0.11 965 060 468 118 – 468 118 3.2%
Tetanus toxoid 20 15 0.03 926 914 179 603 137 831 317 434 2.2%
Yellow fever 10 65 0.82 15 871 37 366 1 248 38 614 0.3%
Total costs with pentavalent 
vaccine
– – – – 13 826 789 601 545 14 428 334 100%
DTP+hep B combination vaccine 10 35 1.23 965 060 5 497 279 210 468 5 707 747 –
Total costs with diphtheria-
tetanus-pertussis-hep B instead 
of pentavalent vaccine
– – – – 6 705 340 506 495 7 211 835 –
Incremental costs of pentavalent 
vaccine compared with DTP+hep B
– – – – 7 121 448 95 050 7 216 499 –
DTP, diphtheria-tetanus-pertussis; hep B, hepatitis B; Hib, Haemophilus influenzae type b.
a  Injection supply costs consist of auto-disable syringes, reconstitution syringes and safety boxes.
distributions with ranges or standard 
deviations respectively (Table 1). Based 
on previous patterns19 and the analysis 
of patient records, a lognormal distribu-
tion was assumed for the treatment cost 
parameters.
One-way sensitivity analyses were 
undertaken to assess the importance of 
herd immunity and vaccine price. In the 
Gambia, invasive Hib disease has been 
eliminated among children aged < 5 
years, despite the fact that the timing 
and coverage of Hib immunizations pre-
dict a direct vaccine protection of only 
41%.20 Most of the observed effective-
ness is therefore attributable to indirect 
protection. We included a scenario of 
zero incidence of Hib disease to illus-
trate the potential long-term impact. 
The pentavalent vaccine price was varied 
to US$ 3 per dose, representing an 18% 
decrease on the 2004 price. We also 
calculated the break-even price.
Results
Impact of Hib vaccine on disease 
incidence
Before the introduction of Hib vaccine, 
the annual incidence per 100 000 
children aged < 5 was estimated at 71 
for Hib meningitis, 61 for Hib non-
meningitic invasive disease and 296 
for non-bacteraemic Hib pneumonia. 
Three years after the introduction these 
incidence estimates were 88% lower at 
8, 7 and 34 respectively. The estimated 
number of cases and deaths for the 2004 
birth cohort with and without Hib vac-
cine are shown in Table 2. Without Hib 
vaccine we estimate that 27 347 children 
would experience Hib disease, resulting 
in 6112 deaths. With the introduction of 
the vaccine these numbers are reduced 
to 3149 cases and 704 deaths. Thus, over 
the first five years of life Hib vaccination 
is preventing 5408 deaths in the 2004 
birth cohort (4% of under-five mortal-
ity). If children did not receive vaccine 
but all had access to hospital care at 
current Kenyan standards, the estimated 
number of deaths would decrease by 
60%, resulting in 2164 deaths prevented 
by Hib vaccination.
Vaccine delivery costs
Costs of vaccine and injection equip-
ment for the six different antigens cur-
rently included in the Kenyan immu-
nization schedule are outlined in Table 
3, together with the costs of a scenario 
using a diphtheria-tetanus-pertussis-hep 
B combination vaccine instead of pen-
tavalent vaccine. The costs of pentavalent 
vaccine amount to 90% of total vaccine 
and injection equipment costs. GAVI 
supported the Kenyan Government with 
US$ 100 000 to finance training and 
communication activities for introduc-
ing new vaccines. The health ministry 
did not introduce post-vaccine surveil-
lance for meningitis other than through 
the externally funded WHO-African 
Region Paediatric Bacterial Meningitis 
Surveillance Network, so we did not 
include additional surveillance costs.
Vaccine and injection equipment 
costs per fully immunized child are 
US$ 14.95 for pentavalent vaccine and 
US$ 7.47 for the diphtheria-tetanus- 
pertussis-hep B vaccine combination.
Treatment costs
The mean lengths of stay for meningi-
tis, non-meningitic invasive disease and 
non-bacteraemic pneumonia patients 
were 11.7 (standard deviation, SD 
6.5), 7.5 (SD 5.7) and 5.7 (SD 5.6) 
days respectively. The drug costs of Hib 
meningitis, non-meningitic invasive Hib 
disease and non-bacteraemic pneumonia 
were US$ 10 (SD 8), US$ 14 (SD 22) 
and US$ 3 (SD 3) respectively. Mean 
total treatment costs were US$ 132 for 
a case of Hib meningitis, US$ 112 for 
non-meningitic invasive Hib disease 
and US$ 48 for non-bacteraemic Hib 
pneumonia.
With current access to health-care 
services, total treatment costs saved due 
to Hib vaccination of the 2004 birth 
cohort amount to US$ 871 539. This 
is 12% of Hib vaccine delivery costs. 
If all Kenyan children had access to 
hospital care, this figure would be US$ 
1 740 769, or 24% of Hib vaccine de-
livery costs.
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Table 4. Incremental cost-effectiveness of Hib vaccine in Kenya: base case scenario (2004)
Vaccine  
and  
injection 
equipment
Treatment 
costs
(US$)
Net costs
(US$)
Hib  
cases
Hib
deaths
Disability 
adjusted 
life years 
(DALYs)
Costs (US$) 
per case 
averted
(95% CI)
Costs (US$) 
per death 
averted
(95% CI)
Costs (US$) 
per DALY 
averted
(95% CI)
Undiscounted results:
No Hib vaccination 7 211 835 984 958 8 196 793 27 347 6 112 401 568 – – –
Hib vaccination 14 428 334 113 419 14 541 753 3 149 704 46 243 – – –
Increment 7 216 499 –871 539 6 344 960 24 198 5 408 355 325 262
(175–455)
1 173
(797–1982)
18
(12–30)
Discounted results (3%):
No Hib vaccination 7 211 835 967 758 6 244 077 26 870 6 005 191 489 – – –
Hib vaccination 14 428 334 111 439 14 316 895 3 094 691 22 052 – – –
Increment 7 216 499 –56 319 6 360 180 23 775 5 314 169 438 268
(178–464)
1 197
(814–2021)
38
(26–63)
CI, confidence interval; Hib, Haemophilus influenzae type b.
Fig. 1. Percentage contribution to variance of uncertain parameters included in 
the analysis for costs per discounted DALY averted
Hib meningitis and non-meningitic
invasive Hib disease incidence
39%
Access to hospital care
44%
Other
22 parameters
4%
Ratio between Hib meningitis
and Hib pneumonia
2%
No access
to health care
9%
Access to
outpatient care
2%
Cost-effectiveness
In the base case scenario the costs per 
discounted case, death and DALY 
averted were US$ 268, US$ 1197 and 
US$ 38 respectively (Table 4).
Uncertainty and sensitivity 
analysis
The 95% prediction interval of certainty 
for the cost per discounted DALY and 
death averted were US$ 26–63 and US$ 
814–2021 respectively (Table 4). Hence, 
if the Kenyan Government considers 
an investment that costs US$ 63 per 
discounted DALY averted to be cost-
effective, Hib vaccine can be considered 
cost-effective with 97.5% certainty.
Fig. 1 illustrates which parameters 
contribute to most of the uncertainty 
in the cost-effectiveness ratios. Of the 
27 variables with a distribution and an 
uncertainty range in the analysis, five 
caused 96% of the variability in the 
costs per discounted DALY averted es-
timate. Three of these are access to care 
parameters. Since the access to hospital 
care parameter affects the disease inci-
dence and the case fatality rates, uncer-
tainty in this parameter causes 44% of 
the uncertainty. Hence, more knowl-
edge about access to care is required 
in order to obtain a more precise cost- 
effectiveness estimate.
Assuming that herd immunity 
would lead to the elimination of Hib 
disease, the cost-effectiveness ratio de-
creases to US$ 1041, US$ 233 and US$ 
33 per discounted death, case and DALY 
averted, respectively. With a pentavalent 
vaccine price of US$ 3 per dose, the 
incremental costs per discounted death 
and DALY averted are US$ 774 and 
US$ 24 respectively. The break-even 
pentavalent vaccine price per dose, where 
incremental Hib vaccination costs equal 
averted treatment costs for Hib disease, 
is US$ 1.82. Hence, a price lower than 
this for Hib vaccination provides govern-
ment health sector savings.
Discussion
The most pressing question faced 
by health policy-makers in Kenya is 
whether Hib vaccine is a priority deserv-
ing public funds. The decision should be 
based on the affordability and estimated 
cost-effectiveness of the vaccine. We 
have found that the costs per discounted 
DALY averted are in the range of US$ 
26–63 at the current vaccine price. By 
all generally used benchmarks, this 
is considered a highly cost-effective 
intervention. WHO suggests that an 
intervention may be considered very 
cost-effective if the costs per discounted 
DALY averted are less than the country’s 
per-capita GDP.21 Hib vaccination easily 
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falls below this benchmark – the per 
capita GDP was US$ 481 in 2004.
A cost-effectiveness analysis is rela-
tive in the sense that one intervention can 
only be considered cost-effective in rela-
tion to another. However, there is little 
cost-effectiveness information on other 
interventions in Kenya for comparison. 
The cost-effectiveness of Hib vaccine is 
comparable to preventive interventions 
against malaria, such as bednets (US$ 
4–85 per discounted DALY)22 and to 
some tuberculosis control strategies (US$ 
13–496 per discounted DALY).23
Our estimates of Hib disease inci-
dence, with and without vaccine, are 
derived from a study monitoring its 
decline in a largely rural district. The 
only plausible explanation for this is 
the provision of Hib vaccine as part of 
the government’s routine immunization 
programme.11 The vaccine’s impact was 
measured from a hospital setting; low 
levels of access to care produce an un-
derestimate of the true disease burden. 
By adjusting the hospital incidence esti-
mates for access to care, we generated a 
considerably higher vaccine impact. We 
believe our estimate of the proportion of 
children having access to inpatient care 
(50%) is conservative given the available 
data.14 There are several other reasons 
why the cost-effectiveness results are 
likely to be underestimates. First, the 
case fatality rate attributed to inpatient 
Hib meningitis (17%) is considerably 
lower than the average reported for sub-
Saharan Africa (27.6%).1 Second, we ac-
count only for serious motor sequelae in 
children with meningitis and not those 
with other invasive Hib disease. Third, 
the cost-effectiveness estimates include 
only the provider’s perspective and do 
not take into account costs borne by 
households.
Many people in low-income coun-
tries consider Hib disease to be relatively 
uncommon and expensive to prevent. 
Our findings indicate that while the 
burden of disease is smaller than for 
diseases such as malaria, so too is the in-
vestment required to prevent the disease. 
Thus, Hib vaccine is as cost-effective as 
any other priority intervention: each life 
saved requires an investment similar to 
that required for impregnated bednets 
to prevent malaria. This analysis should 
encourage action in countries that have 
delayed introducing the vaccine into 
their immunization schedule because 
the costs did not appear to be matched 
by the benefits. The findings indicate to 
manufacturers and donors that a small 
decrease in vaccine price markedly 
improves its cost-effectiveness and that 
pentavalent vaccine would be affordable 
by all if its price was halved.  O
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Résumé
Evaluation économique de la délivrance du vaccin contre Haemophilus influenzae type b par les services 
de vaccination systématique du Kenya
Objectif La vaccination contre Haemophilus influenzae type b 
(Hib) a été intégrée au programme de vaccinations systématiques 
kenyan en 2001. Nous nous sommes efforcés d’estimer le rapport 
coût/efficacité de la délivrance de ce vaccin.
Méthodes Un modèle a été mis au point pour suivre jusqu’à leur 
mort une cohorte d’enfants nés en 2004, vaccinés ou non contre  le 
virus Hib. L’incidence des infections à Hib invasives a été estimée à 
l’hôpital de district de Kilifi et par le biais du système de surveillance 
démographique environnante de la région côtière du Kenya. 
L’incidence nationale des affections à Hib a été estimée à partir 
d’ajustements sur l’incidence observée par la surveillance passive 
dans les hôpitaux et d’hypothèses concernant l’accès aux soins. Les 
taux de létalité ont également été supposés comme dépendants 
de l’accès aux soins. L’étude s’est basée sur un prix d’US$ 3,65 
par dose pour le vaccin pentavalent DTCP + Hib. L’influence sur les 
rapports coût/efficacité des incertitudes sur les paramètres a été 
évaluée par des simulations multivariées de type Monte Carlo.
Résultats Chez les enfants de moins de 5 ans, l’introduction du 
vaccin anti-Hib a permis de réduire l’incidence de la méningite à 
Hib de 71 à 8 cas pour 100 000, celle des affections invasives non 
méningées de 61 à 7 cas pour 100 000 et celle des pneumonies 
à Hib non bactériennes de 296 à 34 cas pour 100 000. Les 
économies réalisées grâce au nombre d’années de vie corrigées 
de l’incapacité (DALY) épargnées et aux décès évités s’élèvent 
respectivement à US$ 38 [intervalle de confiance à 95% (IC) : 
26-63] et à US$ 1197 [intervalle de confiance à 95% (IC) : 814-
2021]. La plus grande part de l’incertitude sur les résultats est 
imputable aux difficultés d’évaluation des paramètres relatifs 
aux soins. Le seuil de rentabilité du vaccin pentavalent (prix pour 
lequel l’économie sur les dépenses entraînées par les infections 
à Hib compense l’augmentation des coûts de vaccination) est 
d’US$ 1,82 par dose.
Conclusion La vaccination contre le virus Hib constitue une 
intervention hautement efficace dans le cas du Kenya. Elle 
permettrait une économie si le prix du vaccin était inférieur de 
50% au moins à son niveau actuel.
Resumen
Evaluación económica de la administración de la vacuna contra Haemophilus influenzae tipo b en los 
servicios de inmunización sistemática de Kenya
Objetivo Estimar la costoeficacia de la administración de la 
vacuna contra Haemophilus influenzae tipo b (Hib), que se 
introdujo en los servicios de inmunización sistemática de Kenya 
en 2001.
Métodos Se elaboró un modelo para seguir la evolución de 
la cohorte de nacimiento de 2004 hasta el momento de la 
defunción, con y sin vacuna anti-Hib. Se estimó la incidencia de 
la enfermedad invasiva por Hib en el Hospital de Distrito de Kilifi 
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y en el sistema circundante de vigilancia demográfica de la costa 
de Kenya. La incidencia nacional de enfermedad por Hib se estimó 
ajustando la incidencia observada mediante vigilancia pasiva en 
los hospitales, asumiendo algunas premisas sobre el acceso a la 
atención. Se asumió que las tasas de letalidad también dependían 
del acceso a la asistencia. Fijando en US$ 3,65 el precio de la dosis 
de vacuna pentavalente contra difteria-tétanos-tos ferina-hep 
B-Hib, se realizaron simulaciones multifactoriales con el método 
de Monte Carlo para determinar el impacto de la incertidumbre 
de los parámetros en los valores de la costo-eficacia.
Resultados La introducción de la vacuna anti-Hib redujo la 
incidencia estimada de meningitis por Hib por 100 000 niños 
menores de 5 años de 71 a 8; de enfermedad invasiva no 
meningítica por Hib, de 61 a 7; y de neumonía por Hib no 
bacteriémica, de 296 a 34. Los costos por AVAD (año de vida 
ajustado en función de la discapacidad) descontado evitado y 
por muerte descontada evitada fueron de US$ 38 (intervalo de 
confianza (IC) del 95%: 26-63) y US$ 1197 (IC95%: 814-2021), 
respectivamente. La mayor parte de la incertidumbre de los 
resultados se debió a la incertidumbre de los parámetros relativos 
al acceso a la atención. El umbral de rentabilidad de la vacuna 
pentavalente -punto de equivalencia del incremento de los costos 
de la vacunación anti-Hib y de los costos evitados en concepto 
de tratamiento de la enfermedad por Hib- fue de US$ 1,82 por 
dosis.
Conclusión La vacunación contra Hib es una intervención 
altamente costoeficaz en Kenya, y permitiría hacer economías si 
la vacuna costara menos de la mitad de lo que cuesta ahora.
صخلم
اينيك في ينيتورلا عينمتلا تامدخ في ةيلزنلا ةيمدتسملل ئيابلا طمنلا حاقل ءاطعلإ يداصتقلاا مييقتلا
 تامدخ  نمض  ةيلزنلا  ةيمدتسملل  ئيابلا  طمنلا  حاقل  لخدأ  دقل  :فدهلا
 ميـيقت وه ةساردلا هذه في انفدهو .2001 ماع ذنم اينيك في ينيتورلا عينمتلا
.حاقللا اذه ءاطعإ ةفلكت ءاقل ةيلاعفلا
 ،مهتافو  ىتح  2004  ماعل  ةدلاولا  بارتأ  ةعباتلم  ًاجذونم  انددعأ  :ةقيرطلا
 ثودح لدعم انر َّدقو ،هاقلتت لم ىرخأ ةعومجمو حاقللا ت َّقلت ةعومجم مهو
 تايفشتسم في ةيلزنلا ةيمدتسملل ئيابلا طمنلا نع ةمجانلا ةيزاغلا ضارملأا
 لحاوسلا في اهب ةطيحلما قطانملل فيارغجلا د ُّصترلا ماظن فيو يفيليك ةعطاقم
 ةيمدتسملل ئيابلا طمنلا نع ةمجانلا ضارملأا ثودح لدعم انردقو .ةينيكلا
 د ُّصترلا قيرط نع هانظحلا يذلا لدعلما حيحصتب ينطولا ىوتسلما لىع ةيلزنلا
 ماك .ةيحصلا ةياعرلا ةحاتإ لوح تامولعم نم ةدافتسلاابو تايفشتسلما في
 انمدختساو .ةيحصلا ةياعرلا ةحاتإ لىع ًادماتعا تلااحلا تايفو تلادعم انردق
 ن َّمضتي  يذلا  ؤفاكتلا  سيماخلا  حاقلل  ًايكيرمأ  ًارلاود  3.65  هرادقم  ًارعس
 )كييدلا لاعسلا( قوهاشلاو )سوناتيتلا( زازكلاو )ايترفدلا( قانُخلا تاحاقل
 ولراك  تنوم  ةاكاحم  ةعومجم  انيرجأو  .ةيلزنلا  ةيمدتسملل  ئيابلا  طمنلاو
 ميقب ةفلكتلا ءاقل ةيلاعفلا بسن لىع حاقللا رثأ ميـيقتل تايرغتلما ةد ِّدعتلما
.ةمدختسلما تاتباثتملل بايترلاا نم
 ضفخ لىإ ةيلزنلا ةيمدتسملل ئيابلا طمنلا حاقل لاخدإ ى َّدأ دقل :تادوجولما
 طمنلا  نم  ةيلزنلا  ةيمدتسلماب  اياحسلا  باهتللا  ةر َّدقلما  ثودحلا  تلادعم
 ضفخو ،8 لىإ 71 نم ةسماخلا نس نود لافطلأا نم فلأ ةئم لك ىدل ئيابلا
 طمنلا نع ةمجانلا ةيئاحسلا يرغ ةيزاغلا ضارملأل ةر َّدقلما ثودحلا تلادعم
 ثودحلا  تلادعم  ضفخو  ،7  لىإ  61  نـم  ةـيلزنلا  ةـيمدتسلما  نم  ئيابلا
 بوحصلما يرغ ةيلزنلا ةيمدتسلما نم ئيابلا طمنلاب يوئرلا باهتللال ةر َّدقلما
 ةـح َّحصلما رمعلا تاونس فيلاكت تناك دقو .34 لىإ 296 نم مدلا مُْثرَجَتب
 ةقث لصافب( ًايكيرمأ ًارلاود 38 اـهصاقنإ نـكمأ يتلا زـجعلا ددـم باـستحاب
 نكمأ يتلا تايفولا فيلاكتو ،)63و 26 ينب ةساقلما ميقلا تحوارت ذإ %95
 ةساقلما ميقلا تحوارت ذإ %95 ةقث ةلصافب( ًايكيرمأ ًارلاود 1197 اهيدافت
 في بايترلاا نع ًماجان جئاتنلا في بايترلاا مظعم ناك دقو .)2021و 814 ينب
 سيماخلا حاقللا رعس في لداعتلا ةطقن نإ .ةيحصلا ةياعرلا ةحاتإ تاتباثتم
 ةيمدتسملل ئيابلا طمنلا حاقلل ةمكاترلما فيلاكتلا اهيف ىواستي يتلاو ؤفاكتلا
 طمنلا نع ةمجانلا ضارملأا ةجلاعلم اهيدافت نكمأ يتلا فيلاكتلا عم ةيلزنلا
.ةعرج لكل ًايكيرمأ ًارلاود 1.82 تناك ةيلزنلا ةيمدتسملل ئيابلا
 ةعيفرلا  تلاخدتلا  نم  ةيلزنلا  ةيمدتسملل  ئيابلا  طمنلا  حاقل  نإ  :جاتنتسلاا
 راعسأ  تناك  اذإ  فيلاكتلل  ًار ِّفوم  نوكيسو  .اينيك  في  ةفلكتلا  ءاقل  ةيلاعفلا
.ضراحلا تقولا في هيلع يذلا ىوتسلما فصن نم لقأ حاقللا
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